Summary
Global Markets Direct’s, ‘Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline Review, H2 2016’, provides an overview of the Cognitive Impairment Associated With Schizophrenia (CIAS) pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Cognitive Impairment Associated With Schizophrenia (CIAS), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Cognitive Impairment Associated With Schizophrenia (CIAS) and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Cognitive Impairment Associated With Schizophrenia (CIAS)
- The report reviews pipeline therapeutics for Cognitive Impairment Associated With Schizophrenia (CIAS) by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Cognitive Impairment Associated With Schizophrenia (CIAS) therapeutics and enlists all their major and minor projects
- The report assesses Cognitive Impairment Associated With Schizophrenia (CIAS) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Cognitive Impairment Associated With Schizophrenia (CIAS)
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Cognitive Impairment Associated With Schizophrenia (CIAS)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Cognitive Impairment Associated With Schizophrenia (CIAS) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
AbbVie Inc.
Amarantus Bioscience Holdings, Inc.
Astellas Pharma Inc.
AstraZeneca Plc
Bristol-Myers Squibb Company
Coronis Partners Ltd.
Eli Lilly and Company
FORUM Pharmaceuticals Inc.
H. Lundbeck A/S
Intra-Cellular Therapies, Inc.
Iproteos S.L.
'
Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Cognitive Impairment Associated With Schizophrenia (CIAS) Overview 10
Therapeutics Development 11
Pipeline Products for Cognitive Impairment Associated With Schizophrenia (CIAS) - Overview 11
Cognitive Impairment Associated With Schizophrenia (CIAS) - Therapeutics under Development by Companies 12
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline Products Glance 14
Clinical Stage Products 14
Early Stage Products 15
Cognitive Impairment Associated With Schizophrenia (CIAS) - Products under Development by Companies 16
Cognitive Impairment Associated With Schizophrenia (CIAS) - Companies Involved in Therapeutics Development 18
AbbVie Inc. 18
Amarantus Bioscience Holdings, Inc. 19
Astellas Pharma Inc. 20
AstraZeneca Plc 21
Bristol-Myers Squibb Company 22
Coronis Partners Ltd. 23
Eli Lilly and Company 24
FORUM Pharmaceuticals Inc. 25
H. Lundbeck A/S 26
Intra-Cellular Therapies, Inc. 27
Iproteos S.L. 28
Luc Therapeutics, Inc. 29
Neuralstem, Inc. 30
Pfizer Inc. 31
Saniona AB 32
SK Biopharmaceuticals Co., Ltd. 33
Spherium Biomed S.L. 34
Sunovion Pharmaceuticals Inc. 35
Takeda Pharmaceutical Company Limited 36
Vanda Pharmaceuticals Inc. 37
Cognitive Impairment Associated With Schizophrenia (CIAS) - Therapeutics Assessment 38
Assessment by Monotherapy Products 38
Assessment by Target 39
Assessment by Mechanism of Action 41
Assessment by Route of Administration 43
Assessment by Molecule Type 45
Drug Profiles 47
A-431404 - Drug Profile 47
Product Description 47
Mechanism Of Action 47
R&D Progress 47
AN-761 - Drug Profile 48
Product Description 48
Mechanism Of Action 48
R&D Progress 48
AQW-051 - Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
ASP-4345 - Drug Profile 51
Product Description 51
Mechanism Of Action 51
R&D Progress 51
ASP-5736 - Drug Profile 52
Product Description 52
Mechanism Of Action 52
R&D Progress 52
AUT-1 - Drug Profile 53
Product Description 53
Mechanism Of Action 53
R&D Progress 53
AUT-6 - Drug Profile 54
Product Description 54
Mechanism Of Action 54
R&D Progress 54
AUT-9 - Drug Profile 55
Product Description 55
Mechanism Of Action 55
R&D Progress 55
AVL-3288 - Drug Profile 56
Product Description 56
Mechanism Of Action 56
R&D Progress 56
davunetide - Drug Profile 57
Product Description 57
Mechanism Of Action 57
R&D Progress 57
DSP-3748 - Drug Profile 58
Product Description 58
Mechanism Of Action 58
R&D Progress 58
eltoprazine - Drug Profile 59
Product Description 59
Mechanism Of Action 59
R&D Progress 59
erteberel - Drug Profile 64
Product Description 64
Mechanism Of Action 64
R&D Progress 64
FRM-17874 - Drug Profile 65
Product Description 65
Mechanism Of Action 65
R&D Progress 65
IC-041 - Drug Profile 66
Product Description 66
Mechanism Of Action 66
R&D Progress 66
IPR-088 - Drug Profile 67
Product Description 67
Mechanism Of Action 67
R&D Progress 67
IPR-19 - Drug Profile 68
Product Description 68
Mechanism Of Action 68
R&D Progress 68
IPRO-001 - Drug Profile 69
Product Description 69
Mechanism Of Action 69
R&D Progress 69
ITI-214 - Drug Profile 70
Product Description 70
Mechanism Of Action 70
R&D Progress 70
LSN-2463359 - Drug Profile 72
Product Description 72
Mechanism Of Action 72
R&D Progress 72
LSN-2814617 - Drug Profile 73
Product Description 73
Mechanism Of Action 73
R&D Progress 73
LUAF-64280 - Drug Profile 74
Product Description 74
Mechanism Of Action 74
R&D Progress 74
NSI-189 - Drug Profile 75
Product Description 75
Mechanism Of Action 75
R&D Progress 75
PF-03463275 - Drug Profile 79
Product Description 79
Mechanism Of Action 79
R&D Progress 79
PF-04958242 - Drug Profile 81
Product Description 81
Mechanism Of Action 81
R&D Progress 81
PNU-120596 - Drug Profile 83
Product Description 83
Mechanism Of Action 83
R&D Progress 83
roflumilast - Drug Profile 84
Product Description 84
Mechanism Of Action 84
R&D Progress 84
SKL-15508 - Drug Profile 89
Product Description 89
Mechanism Of Action 89
R&D Progress 89
SKL-A4R - Drug Profile 90
Product Description 90
Mechanism Of Action 90
R&D Progress 90
Small Molecules to Agonize Dopamine D1 Receptor for Cognitive Impairment Associated with Schizophrenia - Drug Profile 91
Product Description 91
Mechanism Of Action 91
R&D Progress 91
Small Molecules to Agonize NMDA2B for Cognitive Impairment Associated With Schizophrenia - Drug Profile 92
Product Description 92
Mechanism Of Action 92
R&D Progress 92
SP-14040 - Drug Profile 93
Product Description 93
Mechanism Of Action 93
R&D Progress 93
TAK-058 - Drug Profile 94
Product Description 94
Mechanism Of Action 94
R&D Progress 94
TAK-831 - Drug Profile 95
Product Description 95
Mechanism Of Action 95
R&D Progress 95
TAK-915 - Drug Profile 96
Product Description 96
Mechanism Of Action 96
R&D Progress 96
VU-0467154 - Drug Profile 97
Product Description 97
Mechanism Of Action 97
R&D Progress 97
Cognitive Impairment Associated With Schizophrenia (CIAS) - Dormant Projects 98
Cognitive Impairment Associated With Schizophrenia (CIAS) - Discontinued Products 100
Cognitive Impairment Associated With Schizophrenia (CIAS) - Product Development Milestones 101
Featured News & Press Releases 101
Feb 01, 2015: ASCIL Biopharm cooperates in a Project awarded with a “RETOS-Colaboración” grant 101
Jan 27, 2015: Spark, a new public-private project created to develop a drug to fight the cognitive impairment associated with schizophrenia 101
Apr 17, 2013: SK Biopharma Announces FDA's Authorization Of IND For SKL15508 For Treatment Of Cognitive Impairment Associated With Schizophrenia 102
Feb 19, 2013: Intra-Cellular Therapies Completes Phase I Single Rising Dose Trial Of Selective Phosphodiesterase 1 Inhibitor 102
Appendix 103
Methodology 103
Coverage 103
Secondary Research 103
Primary Research 103
Expert Panel Validation 103
Contact Us 103
Disclaimer 104
List of Tables
Number of Products under Development for Cognitive Impairment Associated With Schizophrenia (CIAS), H2 2016 11
Number of Products under Development by Companies, H2 2016 13
Comparative Analysis by Clinical Stage Development, H2 2016 14
Comparative Analysis by Early Stage Development, H2 2016 15
Products under Development by Companies, H2 2016 16
Products under Development by Companies, H2 2016 (Contd..1) 17
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by AbbVie Inc., H2 2016 18
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Amarantus Bioscience Holdings, Inc., H2 2016 19
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Astellas Pharma Inc., H2 2016 20
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by AstraZeneca Plc, H2 2016 21
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Bristol-Myers Squibb Company, H2 2016 22
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Coronis Partners Ltd., H2 2016 23
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Eli Lilly and Company, H2 2016 24
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by FORUM Pharmaceuticals Inc., H2 2016 25
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by H. Lundbeck A/S, H2 2016 26
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Intra-Cellular Therapies, Inc., H2 2016 27
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Iproteos S.L., H2 2016 28
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Luc Therapeutics, Inc., H2 2016 29
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Neuralstem, Inc., H2 2016 30
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Pfizer Inc., H2 2016 31
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Saniona AB, H2 2016 32
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by SK Biopharmaceuticals Co., Ltd., H2 2016 33
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Spherium Biomed S.L., H2 2016 34
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Sunovion Pharmaceuticals Inc., H2 2016 35
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Takeda Pharmaceutical Company Limited, H2 2016 36
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Vanda Pharmaceuticals Inc., H2 2016 37
Assessment by Monotherapy Products, H2 2016 38
Number of Products by Stage and Target, H2 2016 40
Number of Products by Stage and Mechanism of Action, H2 2016 42
Number of Products by Stage and Route of Administration, H2 2016 44
Number of Products by Stage and Molecule Type, H2 2016 46
Cognitive Impairment Associated With Schizophrenia (CIAS) - Dormant Projects, H2 2016 98
Cognitive Impairment Associated With Schizophrenia (CIAS) - Dormant Projects (Contd..1), H2 2016 99
Cognitive Impairment Associated With Schizophrenia (CIAS) - Discontinued Products, H2 2016 100
List of Figures
Number of Products under Development for Cognitive Impairment Associated With Schizophrenia (CIAS), H2 2016 11
Number of Products under Development by Companies, H2 2016 12
Comparative Analysis by Clinical Stage Development, H2 2016 14
Comparative Analysis by Early Stage Products, H2 2016 15
Assessment by Monotherapy Products, H2 2016 38
Number of Products by Top 10 Targets, H2 2016 39
Number of Products by Stage and Top 10 Targets, H2 2016 39
Number of Products by Top 10 Mechanism of Actions, H2 2016 41
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 41
Number of Products by Routes of Administration, H2 2016 43
Number of Products by Stage and Routes of Administration, H2 2016 43
Number of Products by Molecule Types, H2 2016 45
Number of Products by Stage and Molecule Types, H2 2016 45
